Therefore, CAR-T cell therapy targeting CD30 for the treatment of refractory or recurrent CD30-positive PTCL could become a clinical application in the future. The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.